THERAPY OF FELINE LEISHMANIOSIS
  • There are no published controlled studies of FeL therapy.
  • In the absence of evidence indicating otherwise, empirical treatment giving the same drugs recommended for dogs is usually considered effective and apparently safe. Allopurinol (10 mg/kg 12 h or 20 mg/kg 24 h P.O., for at least 6 months) has been more frequently used than meglumine antimoniate (20-50 mg/kg 24 h S.C., for 30 days). These two drugs have also been given in combination.
  • Cats under therapy with allopurinol or meglumine antimoniate should be carefully monitored for any adverse effects.
 

Disclaimer: Information given here on drugs and dosages are based on a consensus of clinical and scientific experience by the LeishVet members. These recommendations have been published in scientific peer-reviewed scientific journals. Veterinary practitioners are requested to check with product leaflets and product registrations in their related country prior to any product selection and initiation of treatment.

 
MONITORING AND PROGNOSIS OF FELINE LEISHMANIOSIS
  • Recurrence of clinical signs may occur; careful monitoring after the end of anti-Leishmania treatment should include physical examination, CBC, biochemical profile, urinalysis and quantitative serology at the frequencies indicated below.
  • The life expectancy of cats with FeL is usually good (years) unless concurrent conditions (neoplasia, FIV/FeLV infections) or complications (renal disease) occur.
 

Follow-up regimen

ACTION FREQUENCY
Physical examination
CBC*
Biochemical profile
Urinalysis including UPC**
At least weekly (meglumine antimoniate) or fortnightly (allopurinol) during the first month of therapy
Every 3 months in the first year or after stopping therapy
Every 6 months after the first year
Quantitative serology Every 3 months in the first year or after stopping therapy
Every 6 months after the first year

* CBC: complete blood count.
** UPC: urinary protein: creatinine ratio.